ADC Therapeutics Q1 2024 Adj EPS $(0.38) Beats $(0.56) Estimate, Sales $18.053M Miss $18.102M Estimate
ADC Therapeutics Q1 2024 Adj EPS $(0.38) Beats $(0.56) Estimate, Sales $18.053M Miss $18.102M Estimate
ADC Therapeutics 2024年第一季度調整後每股收益美元（0.38）超過預期（0.56），銷售額爲1,8053萬美元，低於預期的1,810.2萬美元
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.56) by 32.14 percent. The company reported quarterly sales of $18.053 million which missed the analyst consensus estimate of $18.102 million by 0.27 percent. This is a 4.94 percent decrease over sales of $18.992 million the same period last year.
ADC Therapeutics（紐約證券交易所代碼：ADCT）公佈的季度虧損爲每股0.38美元，比分析師普遍預期的0.56美元（0.56美元）高出32.14％。該公司公佈的季度銷售額爲1,805.3萬美元，比分析師普遍預期的1,810.2萬美元低0.27％。這比去年同期的1899.2萬美元的銷售額下降了4.94％。